Study groups N * GG vs. AA GA vs. AA GG/GA vs. AA GG vs. GA/AA G vs. A
OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P
Total 17 1.217 (0.923-1.605) ‡ <0.001 1.161 (0.991-1.360)‡ <0.001 1.165 (0.932-1.456)‡ <0.001 1.114 (0.948-1.312)‡ <0.001 0.966 (0.829-1.126)‡ <0.001
Cancer type                      
Hepatocellular 2 1.433 (1.100-1.866) 0.851 1.291 (0.992-1.681) 0.771 1.360 (1.059-1.746) 0.796 1.168 (0.996-1.367) 0.920 0.857 (0.761-0.964) 0.983
Gastric 4 1.160 (0.601-2.237)‡ <0.001 1.300 (0.670-2.521)‡ <0.001 1.235 (0.662-2.302)‡ <0.001 1.077 (0.814 -1.508) ‡ 0.042 1.033 (0.696-1.532)‡ <0.001
Colorectal 5 1.028 (0.479-2.207)‡ 0.020 0.805 (0.498- 1.301)‡ 0.006 0.858 (0.543-1.354)‡ 0.006 1.079 (0.804-1.447) 0.215 0.929 (0.727-1.188)‡ 0.060
Esophagus 2 1.004 (0.235-4.295)‡ <0.001 1.454 (1.110-1.906) 0.146 1.194 (0.482-2.957)‡ 0.002 0.809 (0.273-2.398)‡ <0.001 0.708 (0.627-0.799) 0.368
Oral 2 0.725 (0.379-1.385) 0.312 1.086 (0.259-4.554)‡ 0.013 1.017 (0.300-3.449)‡ 0.026 0.876 (0.563-1.364) 0.478 1.058 (0.786-1.424) 0.240
Pancreatic 2 1.976 (1.496-2.611) 0.173 1.433 (1.093-1.879) 0.766 1.668 (1.286-2.164) 0.347 1.502 (1.098-2.054)‡ 0.033 1.394 (1.098-1.770)‡ 0.049
Ethnicity                      
Asian 12 1.240 (0.908-1.695)‡ <0.001 1.164 (0.895- 1.514)‡ <0.001 1.179(0.896-1.551)‡ <0.001 1.139 (0.956 -1.356)‡ <0.001 0.974 (0.807-1.175)‡ <0.001
European 5 1.143 (0.660-1.977)‡ 0.043 0.988 (0.699-1.397)‡ 0.021 1.101(0.776-1.562)‡ 0.029 1.015 (0.763 -1.351) 0.154 0.951 (0.745-1.213) 0.053
Source of Control                      
Population-based 5 1.169 (0.694-1.970)‡ <0.001 1.156 (0.873-1.530)‡ 0.029 1.170(0.800-1.712)‡ <0.001 0.965 (0.678-1.373)‡ <0.001 1.063 (0.802-1.408)‡ <0.001
Hospital-based 12 1.255 (0.901-1.749)‡ 0.001 1.125 (0.828-1.530)‡ <0.001 1.154(0.864-1.541)‡ <0.001 1.257 (1.129-1.399) 0.150 0.919 (0.778-1.086)‡ <0.001
 Abbreviations: CI, confidence interval; OR, odds ratio.
* Studies of comparison,﹩P-value of Q-test for heterogeneity test, ‡ Random model was used.
Table 3: Results of meta-analysis for CTLA-4 + 49G/A polymorphism and digestive cancer risks.
Goto home»